Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

3.44USD
23 Sep 2016
Change (% chg)

$-0.10 (-2.82%)
Prev Close
$3.54
Open
$3.58
Day's High
$3.62
Day's Low
$3.30
Volume
89,948
Avg. Vol
49,093
52-wk High
$7.00
52-wk Low
$1.46

FATE.OQ

Chart for FATE.OQ

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: --
Market Cap(Mil.): $99.40
Shares Outstanding(Mil.): 28.89
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -1.08 -- --
ROI: -58.15 -0.26 13.91
ROE: -83.87 -3.05 14.82

BRIEF-Fate therapeutics files for offer, sale of up to 5.25 mln shares of co's common stock by selling stockholders

* Files for offer and sale of up to 5.25 million shares of co's common stock by selling stockholders - sec filing Source text (http://bit.ly/2cEgfzm) Further company coverage:

Sep 12 2016

BRIEF-Fate Therapeutics reports Q2 2016 financial results

* Fate Therapeutics reports second quarter 2016 financial results

Aug 08 2016

BRIEF-Fate Therapeutics receives patent for human induced pluripotent cells

* Fate Therapeutics announces issuance of U.S. Patent on compositions of human induced pluripotent cells

Jul 26 2016

BRIEF-Fate Therapeutics announces FDA fast track designation for Protmune

* Fate Therapeutics announces FDA fast track designation for Protmune Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 20 2016

BRIEF-Fate Therapeutics appoints Chris Storgard as chief medical officer

* Fate Therapeutics appoints Chris Storgard as chief medical officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 17 2016

BRIEF-Fate Therapeutics qtrly net loss $0.29 per share

* Fate therapeutics reports first quarter 2016 financial results

May 09 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.